Management of hepatic metastasis from colorectal cancers: an update.

摘要: Approximately 50%–60% of patients with colorectal cancers will develop liver lesions in their life span. Despite the potential surgical resection to provide long-term survival this subset patients, only 15%–20% are found be resectable. The introduction new neoadjuvant chemotherapeutic agents and expanding criteria have enhanced overall 5-year from 30% 60% past decade. use technical innovations such as staged resection; portal vein embolization, repeat allowed higher rates bilobar disease. Extrahepatic primary liver-exclusive recurrent disease no longer represent an absolute contraindication resection. role regional therapy using hepatic arterial infusion is being redefined for unresectable Adjuvant chemotherapy combination therapies looked at fresh perspectives. Ablative approaches gained a firm both adjunct management who not candidates. Overall, metastasis requires multimodal approach.